# A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

> **NCT05997342** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** TQB3912 tablets

## Key facts

- **NCT ID:** NCT05997342
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-16
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-05-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997342, "A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05997342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*